2017
P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: IT
Decker R, Goldberg S, Nath S, Husain Z, Lilenbaum R, Schalper K, Chiang A, Altan M, Zelterman D, Kaech S, Herbst R, Gettinger S. P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: IT. Journal Of Thoracic Oncology 2017, 12: s1303-s1304. DOI: 10.1016/j.jtho.2016.11.1843.Peer-Reviewed Original Research
2011
A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome.
Mehnert J, Mortazavi A, Stein M, Donadio A, Zelterman D, McDonough J, Rowen E, Hoimes C, Gibney G, Kelly W. A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome. Journal Of Clinical Oncology 2011, 29: 278-278. DOI: 10.1200/jco.2011.29.7_suppl.278.Peer-Reviewed Original ResearchTransitional cell carcinomaAdvanced transitional cell carcinomaPR/CRDose reductionOral tyrosine kinase inhibitorECOG PS 0Grade 3/4 neutropeniaHand-foot syndromePhase II trialProgression-free intervalMedian age 64Tyrosine kinase inhibitorsAnti-angiogenic propertiesECOG 0Evaluable diseaseMaintenance SNeutropenic feverNonhematologic toxicityHematologic toxicityMaintenance therapyPrimary endpointSecondary endpointsStable diseaseII trialPS 0
2006
2052 A Phase II Trial of Mammosite Breast Brachytherapy Optimization in the Treatment of Stage 0, I and II Breast Carcinoma
Weidhaas J, Ponn T, Chen Z, Martel M, Zelterman D. 2052 A Phase II Trial of Mammosite Breast Brachytherapy Optimization in the Treatment of Stage 0, I and II Breast Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2006, 66: s239. DOI: 10.1016/j.ijrobp.2006.07.455.Peer-Reviewed Original Research